Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Moodys
Cipla
Cerilliant
Daiichi Sankyo
AstraZeneca
Federal Trade Commission
Chubb
QuintilesIMS

Generated: October 18, 2018

DrugPatentWatch Database Preview

Chiesi Usa Inc Company Profile

« Back to Dashboard

What is the competitive landscape for CHIESI USA INC, and when can generic versions of CHIESI USA INC drugs launch?

CHIESI USA INC has nine approved drugs.

There are twenty US patents protecting CHIESI USA INC drugs.

Summary for Chiesi Usa Inc
US Patents:20
Tradenames:12
Ingredients:6
NDAs:9
Patent Litigation for Chiesi Usa Inc: See patent lawsuits for Chiesi Usa Inc

Drugs and US Patents for Chiesi Usa Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi Usa Inc KENGREAL cangrelor POWDER;INTRAVENOUS 204958-001 Jun 22, 2015 RX Yes Yes 9,925,265 ➤ Try a Free Trial ➤ Try a Free Trial
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-002 Aug 1, 2008 RX Yes Yes 8,658,676 ➤ Try a Free Trial Y ➤ Try a Free Trial
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-001 Aug 1, 2008 RX Yes Yes 8,658,676 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Chiesi Usa Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chiesi Usa Inc CARDENE SR nicardipine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020005-003 Feb 21, 1992 3,985,758 ➤ Try a Free Trial
Chiesi Usa Inc CARDENE nicardipine hydrochloride INJECTABLE;INJECTION 019734-001 Jan 30, 1992 3,985,758 ➤ Try a Free Trial
Chiesi Usa Inc CARDENE nicardipine hydrochloride INJECTABLE;INJECTION 019734-001 Jan 30, 1992 5,164,405 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for CHIESI USA INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 2.5 mg/mL, 10 mL Ampoules ➤ Subscribe 2006-12-27
➤ Subscribe Inhalation Solution 300 mg/4 mL ➤ Subscribe 2017-08-31
➤ Subscribe Injection 0.1 mg/mL, 200 mL and0.2mg/mL, 200 mL ➤ Subscribe 2013-06-20

Supplementary Protection Certificates for Chiesi Usa Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
678 Luxembourg ➤ Try a Free Trial PRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725
209 Luxembourg ➤ Try a Free Trial PRODUCT NAME: CLEVIDIPINE SOUS TOUTES LES FORMES PROCURANT UNE PROTECTION A PARTIR DU BREVET DE BASE
00722 Netherlands ➤ Try a Free Trial PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Boehringer Ingelheim
Fuji
Merck
Deloitte
Farmers Insurance
Federal Trade Commission
QuintilesIMS
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.